GlassScriptPhysician profile
Kimberly Tanner
NPI 1922649235
$4,979.28
in general payments reported to CMS, 2019-2025
35 companies · $76.18 in 2025
The $76.18 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,197 · 2022: $1,240 · 2023: $1,546 · 2024: $920 · 2025: $76.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,441 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,440.59 |
| Education | $101.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.22 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $582.49 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $421.08 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $333.07 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.69 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $279.42 | 2022 | |
| Xeris Pharmaceuticals, INC. | $205.22 | 2022-2024 | Keveyis, Gvoke Hypopen |
| Astellas Pharma US INC | $196.58 | 2021-2024 | Veozah |
| Lilly USA, LLC | $187.80 | 2021-2024 | Jardiance, Emgality, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $184.86 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.80 | 2021-2024 | Jardiance, Ofev |
| Amarin Pharma, INC. | $119.02 | 2021 | |
| Merck Sharp & Dohme LLC | $109.85 | 2021-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $98.33 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $83.44 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $72.42 | 2022-2023 | Quviviq |
| Dexcom, INC. | $70.13 | 2022-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $69.63 | 2023 | Krystexxa |
| Sumitomo Pharma America, INC. | $58.72 | 2023 | Gemtesa |
| Janssen Pharmaceuticals, INC | $51.06 | 2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $43.11 | 2021 | |
| Sunovion Pharmaceuticals INC. | $36.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $35.48 | 2022-2023 | |
| Eisai INC. | $27.73 | 2021 | |
| Acella Pharmaceuticals, LLC | $27.69 | 2023-2024 | NP Thyroid 60 |
| Currax Pharmaceuticals LLC | $27.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.19 | 2021 | |
| Mayne Pharma Commercial LLC | $23.75 | 2023 | |
| Endo Pharmaceuticals INC. | $20.64 | 2021 | |
| Sanofi Pasteur INC. | $17.73 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $15.27 | 2022 | |
| Esperion Therapeutics, INC. | $15.26 | 2021 | |
| Daiichi Sankyo INC. | $14.21 | 2023 | Injectafer |
| Eyevance Pharmaceuticals LLC | $12.37 | 2021 | |
| Hikma Pharmaceuticals USA | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.